51. Bowman M.A., Pearle D.L. Changes in drug prescribing patterns related to commercial company funding of continuing medical education. J Contin Educ Health Prof. 1988; 8: 13–20.

52. Bowman M.A. The impact of drug company funding on the content of continuing medical education. Möbius. 1986; 6: 66–9.

53. Can I buy you a dinner? Pharmaceutical companies increasingly use doctors’ talks as sales pitches. 2005 Aug. Available online at: www.worstpills.org (accessed August 2005).

54. Tramèr M.R., Reynolds D.J., Moore R.A., et al. Impact of covert duplicate publication on metaanalysis: a case study. BMJ. 1997; 315: 635–40.

55. Aspinall R.L., Goodman N.W. Denial of effective treatment and poor quality of clinical information in placebo controlled trials of ondansetron for postoperative nausea and vomiting: a review of published trials. BMJ. 1995; 311: 844–6.

56. Carlisle J., Stevenson C.A. Drugs for preventing postoperative nausea and vomiting. Cochrane Database Syst Rev. 2006; 3: CD004125.

57. Carlisle J.B. A meta-analysis of prevention of postoperative nausea and vomiting: randomized controlled trials by Fujii et al. compared with other authors. Anaesthesia. 2012; 67: 1076–90.

58. Does anesthesiology have a problem? Final version of report suggests Fujii will take retraction record, with 172. Retraction Watch. 2012 July 3.

59. Boseley S. Junket time in Munich for the medical profession – and it’s all on the drug firms. The Guardian. 2004 Oct 5.

60. Studdert D.M., Mello M.M., Brennan T.A. Financial confl icts of interest in physicians’ relationships with the pharmaceutical industry – self-regulation in the shadow of federal prosecution. N Engl J Med. 2004; 351: 1891–900.

61. Kassirer J.P. On the Take: how medicine’s complicity with big business can endanger your health. Oxford: Oxford University Press; 2005.

62. Smith R. The Trouble with Medical Journals. London: Royal Society of Medicine; 2006.

63. Heissel A. [‘The bomb’ has been defused]. Dagens Medicin. 2011 Feb 4.

64. Graudal N., Jürgens G. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. Arthritis Rheum. 2010; 62: 2852–63.

65. Tanne J.H. FDA approves prostate cancer ‘vaccine’ treatment. BMJ. 2012; 340: 998.

66. Hodi F.S., O’Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711–23.

67. Andersen N.V. [Drug with trivial effect]. Politiken. 2012 Feb 5.

68. Rasmussen L.I. [‘How can Henrik Dibbern believe that I have interests in the company?’] Ugeskr Læger. 2012; 174: 248–9.

69. Cuatrecasas P. Drug discovery in jeopardy. J Clin Invest. 2006; 116: 2837–42.

70. Sullivan R., Peppercorn J., Sikora K., et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011; 12: 933–80.

71. Gøtzsche P.C., Johansen H.K. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. Cochrane Database Syst Rev. 2010; 7: CD007851.

72. Jensen J.H., Korsgaard P. [We would drop chemotherapy and enjoy life]. Ekstra Bladet. 2012 March 16.

73. Dreier J. [Chemotherapy or not?]. Danish Cancer Society. 2012 March 19.

74. Slevin M.L., Stubbs L., Plant H.J., et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ. 1990; 300: 1458–60.

75. Watts G. Why the exclusion of older people from clinical research must stop. BMJ. 2012; 344: e3445.

76. Temel J.S., Greer J.A., Muzikansky A., et al. Early palliative care for patients with metastatic nonsmall-cell lung cancer. N Engl J Med. 2010; 363: 733–42.

77. Lenzer J. Spin doctors soft pedal data on antihypertensives. BMJ. 2003; 326: 170.

78. Järhult B, Lindahl S.–O. [Doxazosin and heart failure: trustworthy information for patients’sake]. Läkartidningen. 2003; 48: 4011–12.

79. Fretheim A., Aaserud M., Oxman A.D. The potential savings of using thiazides as the first choice antihypertensive drug: cost-minimisation analysis. BMC Health Services Research. 2003; 3: 18.

80. Drachmann H., Andersen N.V. [Millions to spare on drugs]. Politiken. 2003 Dec 27.

81. Hagerup A. [Focus: drugs]. Ugeskr Læger. 2009; 171: 203–5.

82. Lindberg M. [Interesting statements by Hans Ibsen and Novartis related to new rules for reimbursement of drugs]. Ugeskr Læger. 2010; 172: 2476.

83. Ebdrup N. [Cheap antihypertensives equally good as expensive ones]. Videnskab.dk. 2012 April 13.

84. Gøtzsche P.C. Reply. Ugeskr Læger. 2011; 173: 599.

85. Boseley S. Concern over cancer group’s link to drug firm. The Guardian. 2006 Oct 18.

86. Coleman M. New drugs and survival: does the Karolinska report make sense? Cancer World. 2006 Sept–Oct: 26–35.

87. Gøtzsche P.C. Mammography Screening: truth, lies and controversy. London: Radcliffe Publishing; 2012.

88. US Department of Justice. Danish pharmaceutical Novo Nordisk to pay $25 million to resolve allegations of off-label promotion of Novoseven. 2011 June 10.

89. Christenson S., Finley D. Drug fi rm’s wooing made whistleblower suspicious: Fort Sam doctor was early backer of medication to halt bleeding. San Antonio Express. 2011 June 26.

90. Boffard K.D., Riou B., Warren B., et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma. 2005; 59: 8–18.

91. Webert K.E., Blajchman M.A. Randomized trials in patients with blunt and penetrating trauma. J. Trauma. 2006; 60: 242–3.

92. Andersen N.V., Ellesøe M. [Novo blockbuster buried]. Mandag Morgen. 2008; 27: 9–13.

93. Tedesco J. Military medicine scheme is alleged: S.A. nonprofit tied to alleged scam to influence decisions by doctors. San Antonio Express. 2011 July 20.

94. Mogensen T. [Who is guarding the guardian?]. Ugeskr Læger. 2008; 170: 3076.